PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27071708-12 2016 In addition, hypermethylation has been observed for the same genes in PAs and PCs (e.g. SFRP1, CDKN2A and WT1). Protactinium 70-73 cyclin dependent kinase inhibitor 2A Homo sapiens 95-101 34190396-3 2021 The results confirmed that hepatocyte senescence occurred in HFD-fed Golden hamsters and PA-treated LO2 cells as manifested by increased levels of senescence marker SA-beta-gal, p16 and p21, heterochromatin marker H3K9me3, DNA damage marker gamma-H2AX and decreased activity of telomerase. Protactinium 89-91 cyclin dependent kinase inhibitor 2A Homo sapiens 178-181 21610151-5 2011 RESULTS: Our results indicate that PAs are senescent as evidenced by marked senescence-associated acidic beta-galactosidase activity, low KI-67 index, and induction of p16(INK4a) but not p53 in the majority of 52 PA samples (46 of 52; 88.5%). Protactinium 35-38 cyclin dependent kinase inhibitor 2A Homo sapiens 168-171 21610151-5 2011 RESULTS: Our results indicate that PAs are senescent as evidenced by marked senescence-associated acidic beta-galactosidase activity, low KI-67 index, and induction of p16(INK4a) but not p53 in the majority of 52 PA samples (46 of 52; 88.5%). Protactinium 35-38 cyclin dependent kinase inhibitor 2A Homo sapiens 172-177 21610151-10 2011 We show that it is triggered in PAs through p16(INK4a) pathway induction following aberrant MAPK activation. Protactinium 32-35 cyclin dependent kinase inhibitor 2A Homo sapiens 44-47 21610151-10 2011 We show that it is triggered in PAs through p16(INK4a) pathway induction following aberrant MAPK activation. Protactinium 32-35 cyclin dependent kinase inhibitor 2A Homo sapiens 48-53 15608367-2 2004 The purpose of the study was to compare the prevalence of p16 and K-ras mutation in PA and CP in order to evaluate their usefulness in differential diagnosis of those diseases. Protactinium 84-86 cyclin dependent kinase inhibitor 2A Homo sapiens 58-61 15608367-6 2004 Prevalence of p16 mutations in patients with PA was 18 (78,3%) and with CP - 7 (33,3%) (p<0,01). Protactinium 45-47 cyclin dependent kinase inhibitor 2A Homo sapiens 14-17 8923213-7 1996 Expression of mRNA for the tissue inhibitor of metalloproteinases (TIMP)-1, and of the smaller of two mRNA species for the PA inhibitor PAI-1, ceased by P14. Protactinium 123-125 cyclin dependent kinase inhibitor 2A Homo sapiens 153-156 20044755-6 2010 Neither 1p, 9p, and 10q nor 19q showed significant association with outcome in PAs, although p16 deletion was more common in PAs of the midbrain, brainstem, and spinal cord. Protactinium 125-128 cyclin dependent kinase inhibitor 2A Homo sapiens 93-96